Lilly’s $19.80 billion quarterly revenue was driven by Mounjaro and Zepbound, while JNJ’s $24.062 billion reflected broader portfolio strength.
Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.5% year over year, fueled by GLP-1 drugs Mounjaro ($8.66 billion) and Zepbound ($4.16 billion). Non-GAAP EPS reached $8.55, with CEO David Ricks highlighting the FDA approval of Foundayo, an oral GLP-1 pill.
Johnson & Johnson posted $24.062 billion in revenue, a 9.9% increase, split between Innovative Medicine ($15.426 billion) and MedTech ($8.636 billion). Key contributors included DARZALEX ($3.964 billion) and TREMFYA, showcasing a diversified growth strategy compared to Lilly’s GLP-1 concentration.
Both companies raised guidance, with Lilly committing $6 billion to expand GLP-1 production in Alabama and partnering with NVIDIA on drug discovery. JNJ extended its dividend streak to 64 years, reinforcing its appeal as a lower-beta income stock.